MedTrace Logo

Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients

NCT05611892 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2025-12-12

No results posted yet for this study

Summary

In this study, the investigators will assess the hypothesis that this new positron emission tomography (PET) radiopharmaceutical, 18F-Fluorodeoxysorbitol (18F-FDS), will specifically localize at sites of Gram-negative bacterial due to Enterobacterales and invasive mold infections (e.g. invasive aspergillosis/mucormycosis).

Conditions

  • Enterobacterial Infections
  • Oncologic Disease
  • Inflammatory Disease
  • Invasive Fungal Infections

Interventions

COMBINATION_PRODUCT

18F-FDS PET/CT

20 millicurie (mCi) of 18F-FDS in adult patient age group and 2.5 mCi in children (age 12-18 years old) followed by a PET/CT scan.

Sponsors & Collaborators

Principal Investigators

  • Sanjay K Jain, MD · Johns Hopkins University

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-22
Primary Completion
2025-10-28
Completion
2025-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05611892 on ClinicalTrials.gov